Presentation and poster include deeper data insights on sabirnetug safety profile, target engagement and fluid biomarker changes Presentation to be featured during AAN Emerging Science Session Company on track to initiate Phase 2 trial evaluating sabirnetug in first half of 2024 CHARLOTTESVILLE, Va., April 16, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company... Read More